Tim Cortese

Articles

Sentinel Lymph Node Biopsy Omission Shows Feasibility in Select HR+ Breast Cancer

December 15th 2025

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

DREAMM-8 Study Triplet Sustains PFS, MRD-negativity in R/R Multiple Myeloma

December 14th 2025

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

Resection of MRI-Detected Disease Fails to Improve Recurrence Rates in Early Breast Cancer

December 11th 2025

Locoregional recurrence-free rates were similar in newly diagnosed breast cancer, irrespective of resection of MRI-detected disease.

Talquetamab Plus Teclistamab Displays Activity in R/R Multiple Myeloma With True EMD

December 8th 2025

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer

October 19th 2025

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Pembrolizumab Plus Paclitaxel +/– Bevacizumab Yields Survival Advantages in Recurrent PROC

October 18th 2025

Pembrolizumab and paclitaxel with or without bevacizumab led to PFS and OS benefits vs placebo in place of pembrolizumab in recurrent, PD-L1–positive PROC.

Sevabertinib Yields Robust Responses in HER2-Mutant Advanced NSCLC

October 17th 2025

Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma

September 20th 2025

Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma

September 19th 2025

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

Fixed-Duration Cevostamab After CAR T-Cell Therapy Is Well Tolerated in Heavily Pretreated Myeloma

September 18th 2025

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma

September 18th 2025

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC

July 18th 2025

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

Metastasis-Directed Radiotherapy Yields Durable Disease Control Without Systemic Therapy in Oligometastatic RCC

July 18th 2025

Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL

June 13th 2025

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

June 3rd 2025

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer

June 2nd 2025

Dostarlimab/chemotherapy plus maintenance niraparib showed clinically modest PFS improvements vs niraparib alone in newly diagnosed advanced ovarian cancer.

Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC

June 2nd 2025

Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.

Nivolumab Plus Relatlimab Penetrates Blood-Brain Barrier in PD-(L)1-Refractory Melanoma With Brain Metastases

June 1st 2025

Nivolumab plus relatlimab generated favorable intracranial responses in patients with advanced PD-(L)1-refractory melanoma with brain metastases.

Adagrasib Plus Pembrolizumab Generates Responses in KRAS G12C+ NSCLC

June 1st 2025

Adagrasib plus pembrolizumab was efficacious in patients with KRAS G12C-mutant NSCLC.

T-DXd Maintains Efficacy in HR+/HER2-Low or HER2-Ultralow Breast Cancer Irrespective of Mutational Subtype

June 1st 2025

T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.